Top Markets
#1 Nesa Nesa +437.05%
#2 Prom Prom +32.69%
#3 MetaDAO MetaDAO +29.39%
#4 Bedrock Bedrock +12.45%
#5 Pons Pons +12.01%
#6 dogwifhat dogwifhat +11.31%
#7 Venom Venom +10.88%
#8 Cash Cat Cash Cat +9.94%
#9 Utya Utya +9.83%
#10 cat in a dogs world cat in a dogs world +9.57%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Celltrion, Inc. Celltrion, Inc.

Celltrion, Inc.

068270
Kedudukan dalam Saham #829
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Harga Saham
$132.70
Modal Pasaran
$30.43B
Perubahan (1 hari)
-1.08%
Perubahan (1 tahun)
11.12%
Negara
KR
Perdagangan Celltrion, Inc. (068270)

Kategori

Healthcare
Sejarah hasil dividen untuk Celltrion, Inc. (068270)
Hasil dividen (TTM) bagi Celltrion, Inc. (simbol saham: 068270) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Celltrion, Inc. (068270) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH